Literature DB >> 24945038

A reevaluation of the costs of heart failure and its implications for allocation of health resources in the United States.

Jeff Voigt, M Sasha John, Andrew Taylor, Mitchell Krucoff, Matthew R Reynolds, C Michael Gibson.   

Abstract

The annual cost of heart failure (HF) is estimated at $39.2 billion. This has been acknowledged to underestimate the true costs for care. The objective of this analysis is to more accurately assess these costs. Publicly available data sources were used. Cost calculations incorporated relevant factors such as Medicare hospital cost-to-charge ratios, reimbursement from both government and private insurance, and out-of-pocket expenditures. A recently published Atherosclerosis Risk in Communities (ARIC) HF scheme was used to adjust the HF classification scheme. Costs were calculated with HF as the primary diagnosis (HF in isolation, or HFI) or HF as one of the diagnoses/part of a disease milieu (HF syndrome, or HFS). Total direct costs for HF were calculated at $60.2 billion (HFI) and $115.4 billion (HFS). Indirect costs were $10.6 billion for both. Costs attributable to HF may represent a much larger burden to US health care than what is commonly referenced. These revised and increased costs have implications for policy makers.

Entities:  

Mesh:

Year:  2014        PMID: 24945038      PMCID: PMC6649426          DOI: 10.1002/clc.22260

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  40 in total

Review 1.  Injectable Hydrogels for Cardiac Tissue Engineering.

Authors:  Brisa Peña; Melissa Laughter; Susan Jett; Teisha J Rowland; Matthew R G Taylor; Luisa Mestroni; Daewon Park
Journal:  Macromol Biosci       Date:  2018-05-07       Impact factor: 4.979

2.  Learning Clinical Workflows to Identify Subgroups of Heart Failure Patients.

Authors:  Chao Yan; You Chen; Bo Li; David Liebovitz; Bradley Malin
Journal:  AMIA Annu Symp Proc       Date:  2017-02-10

3.  Cost-Effectiveness of Remote Cardiac Monitoring With the CardioMEMS Heart Failure System.

Authors:  Jordana K Schmier; Kevin L Ong; Gregg C Fonarow
Journal:  Clin Cardiol       Date:  2017-03-08       Impact factor: 2.882

4.  Systematic review of economic burden of heart failure.

Authors:  Asrul Akmal Shafie; Yui Ping Tan; Chin Hui Ng
Journal:  Heart Fail Rev       Date:  2018-01       Impact factor: 4.214

Review 5.  Cardiotoxicity of cancer chemotherapy: identification, prevention and treatment.

Authors:  Diwakar Jain; Tauseef Ahmad; Mitchel Cairo; Wilbert Aronow
Journal:  Ann Transl Med       Date:  2017-09

Review 6.  Cardiac Complications of Cancer Therapy: Pathophysiology, Identification, Prevention, Treatment, and Future Directions.

Authors:  Diwakar Jain; Raymond R Russell; Ronald G Schwartz; Gurusher S Panjrath; Wilbert Aronow
Journal:  Curr Cardiol Rep       Date:  2017-05       Impact factor: 2.931

7.  The cost of inpatient management of heart failure patients: a microcosting study in the Irish healthcare setting.

Authors:  R B Morgan; L McCullagh; M Barry; C Daly
Journal:  Ir J Med Sci       Date:  2016-11-19       Impact factor: 1.568

8.  Cost-effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events.

Authors:  Thomas S G Sehested; Jenny Bjerre; Seul Ku; Andrew Chang; Alison Jahansouz; Douglas K Owens; Mark A Hlatky; Jeremy D Goldhaber-Fiebert
Journal:  JAMA Cardiol       Date:  2019-02-01       Impact factor: 14.676

9.  Patients' annual income adequacy, insurance premiums and out-of-pocket expenses related to heart failure care.

Authors:  Ubolrat Piamjariyakul; Donna Macan Yadrich; Christy Russell; Jane Myer; Chanawee Prinyarux; James L Vacek; Edward F Ellerbeck; Carol E Smith
Journal:  Heart Lung       Date:  2014-07-08       Impact factor: 2.210

10.  The role and clinical effectiveness of multimodality imaging in the management of cardiac complications of cancer and cancer therapy.

Authors:  Raymond R Russell; Jonathan Alexander; Diwakar Jain; Indu G Poornima; Ajay V Srivastava; Eugene Storozynsky; Ronald G Schwartz
Journal:  J Nucl Cardiol       Date:  2016-06-01       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.